Spexis AG (XSWX:SPEX) Treasury Stock : CHF0.00 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Spexis AG Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Spexis AG's treasury stock for the quarter that ended in Dec. 2023 was CHF0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Spexis AG Treasury Stock Historical Data

The historical data trend for Spexis AG's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spexis AG Treasury Stock Chart

Spexis AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

Spexis AG Semi-Annual Data
	Dec13	Dec14	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Treasury Stock	Get a 7-Day Free Trial													-	-	-	-	-

Spexis AG Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Spexis AG (XSWX:SPEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spexis AG (XSWX:SPEX) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

SPEXz:UK

Address

Hegenheimermattweg 125, Allschwil, CHE, CH-4123

Website

https://www.polyphor.com

Spexis AG is a clinical-stage biopharmaceutical company. The company is engaged in the discovery and development of antibiotics and other specialty pharma products for severe or life-threatening diseases. The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research and development and prospective commercialization of respiratory therapeutics addressing high unmet medical needs.

Spexis AG (XSWX:SPEX) Headlines

No Headlines